![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HD Lighthouse Contributing Editor's Comment: As a major step towards treatments, HD researchers engineered mouse models of the disease by adding CAG repeats. Researchers Scott Zeitlin and Erin Clabough have now engineered a mouse without any CAG repeats in the region of the huntingtin's gene where excessive CAG repeats cause HD in people. The mice developed normally in utero unlike mice engineered to lack the huntingtin's gene altogether who die in utero. The huntingtin's protein is necessary for embryonic development, but the CAG repeats are not. In adulthood, however, the CAG-depleted mice exhibited mild memory and learning deficits but actually performed better on the rotarod, a standard measure of motor performance, than normal mice. The researchers suggest that the function of the CAG repeat is related to the regulation of energy within the cell. Examining cells in culture, they found that there were higher levels of ATP (adenosine triphosphate - cellular energy) present, but that the cells aged more quickly. As RNA interference technologies improve and advance toward human clinical trials, it is important for researchers to learn all they can about the normal function of the huntingtin's protein and the role of the CAG repeats. This study shows that developing a technique to knock out the CAG regions in the normal and HD gene would not be a good therapeutic strategy. -- Marsha L. Miller, Ph.D.
Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellularErin B.D. Clabough and Scott O. Zeitlin Source: Human Molecular Genetics 2006 15(4):607-623
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Research related HD and it's general affect on the brain
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
25 Jul 2010
Sirtuin Inhibition Achieves Neuroprotection by Decreasing Sterol Biosynthesis
SIRT2 inhibition emerges as a promising therapeutic strategy. 24 May 2010
Cargo Recognition is Impaired in HD
Autophagy increases but is impaired, leading to an increase of the HD protein in the cytosol. 22 Dec 2009
Invitation to participate in a quality of life survey
Here is an opportunity to tell the medical professionals about quality of life issues. 6 Dec 2009
An interview with Dr. Jan Nolta
A trial of mesenchymal stem cell is planned for the end of 2010. 5 Dec 2009
Mesenchymal stem cells repair neurotoxin damage in an animal model
Preclinical work supports the use of mesenchymal stem cells to treat neurodegenerative disorders. 5 Dec 2009
The search for genetic modifiers
The search for genetic modifiers is an important part of the effort to find treatments. 20 Sep 2009
Axonal transport impaired in HD
Researchers have identified the mechanism by which axonal transport is impaired in neurons in HD. 4 Jul 2009
Rhes and the HD protein
Researchers at Johns Hopkins have discovered that a protein called rhes binds to the HD protein and causes toxicity. 24 Apr 2009
Acetylation of the HD protein
MSG-MIND researchers discover a new therapeutic target: increased acetylation enhances clearance of the HD ptotein from the nucleus. 31 Jan 2009
Impaired ERAD and ER stress
Cell model study shows that impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. All Updates for General | |||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|